Is Wuxi FDA approved?
Facilities operated by WuXi enterprises have successfully cleared numerous regulatory inspections and pre-license assessments conducted by the United States Food and Drug Administration (FDA). Multiple manufacturing plants and drug substance laboratories managed by the group have maintained high regulatory compliance records, securing formal approvals and facility licenses that enable them to produce clinical and commercial batches for the highly regulated American pharmaceutical market.
Related FAQs
WuXi AppTec operates as a leading global contract research, development, and manufacturing organization, providing critical laboratory research and production services to the pharmaceutical, biotechnology, and medical device industries.
WuXi AppTec Co., Ltd. officially completed its major A-share initial public offering and commenced trading on the Shanghai Stock Exchange on May 8, 2018, subsequently listing shares on the Hong Kong Stock Exchange later that year.
Wuxi, located in China's Jiangsu province, is widely considered an exceptionally safe, orderly, and modern metropolitan city for residents, business travelers, and expatriates.
Hexagon AB operates with a global workforce numbering approximately sixteen thousand one hundred eighteen employees following strategic restructuring and portfolio realignments.
The United States Department of Defense maintains a designated roster of Chinese military companies under Section 1260H, identifying entities operating directly or indirectly in the US that are tied to China's military-civil fusion strategy.
Wuxi is a major historic and economically vibrant city located in Jiangsu Province, China, globally known for its stunning natural scenery surrounding Lake Tai and its crucial role as a cradle of modern Chinese industry and commerce.
WuXi AppTec is an entirely legitimate, multi-billion-dollar enterprise that provides vital scientific research, testing, and manufacturing services to a massive share of the world's leading pharmaceutical corporations.
Generally, Wyndham timeshares are not considered financial investments in the traditional sense, as they are not designed to increase in resale value like stocks or real estate.
Directors and operational leaders managing healthcare programs, clinical services, or business operations at Centene Corporation earn robust professional compensation packages.
WuXi AppTec delivered robust financial results, reporting significant year-over-year revenue and profit growth driven by its unique, fully integrated Contract Research, Development, and Manufacturing Organization platform strategy.
IQVIA Holdings Inc. is widely recognized as the largest contract research organization and health information technology services provider in the world.
No, WuXi XDC is a subsidiary and joint venture, not the same entity as WuXi Biologics. It is formed as a joint venture between WuXi Biologics (60% stake) and WuXi STA (40% stake) to focus specifically on the R&D and manufacturing of bioconjugates.
The United States Department of Defense added WuXi AppTec to its updated roster of entities designated as Chinese military companies.
The geographic place name Wuxi, which designates a major historical city located in Jiangsu Province, China, translates literally from Chinese characters as "no tin.
WuXi AppTec Co., Ltd., a major global provider of laboratory and manufacturing services supporting pharmaceutical and medical device research and development, maintains a dual-listing corporate structure.
WuXi AppTec, the prominent global pharmaceutical and medical device research and manufacturing outsourcing enterprise, was officially founded in December 2000 by Dr. Ge Li and a team of co-founders in Shanghai, China.
Principal research scientists, vice presidents of drug discovery, and chief scientific officers lead the pharmaceutical research hierarchy with the highest compensation figures.
WuXi AppTec operates as an integrated contract research, development, and manufacturing organization (CRDMO), encompassing full-service contract research organization (CRO) capabilities alongside contract development and manufacturing services.
WuXi AppTec divested its China-based clinical research services subsidiaries, including WuXi Clinical and WuXi MedKey, through a definitive agreement with a global private asset manager.
The Section 1260H list refers to an official roster compiled and periodically updated by the United States Department of Defense identifying Chinese military companies operating directly or indirectly within the United States.
Employee compensation packages at Wynn Resorts and associated luxury entertainment properties vary widely depending on specific hospitality departments, gaming operations, technical support roles, and corporate administration.
WuXi AppTec is a major multinational pharmaceutical, biopharmaceutical, and medical device research and development services enterprise headquartered in Shanghai, China.
WuXi AppTec operates as a publicly traded commercial enterprise with a diverse global shareholder base consisting of international institutional investors, mutual funds, and retail traders.